Trxade Health Inc (MEDS) Stocks Reach New Highs at $10.24 During Trading Session

After finishing at $9.55 in the prior trading day, Trxade Health Inc (NASDAQ: MEDS) closed at $10.24, up 7.23%. In other words, the price has increased by $+0.69 from its previous closing price. On the day, 113108 shares were traded.

Ratios:

Our goal is to gain a better understanding of MEDS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.28 and its Current Ratio is at 0.61. In the meantime, Its Debt-to-Equity ratio is 0.56 whereas as Long-Term Debt/Eq ratio is at 0.09.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MEDS now has a Market Capitalization of 11.51M and an Enterprise Value of 17.96M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.36 while its Price-to-Book (P/B) ratio in mrq is 0.73. Its current Enterprise Value per Revenue stands at 1.92 whereas that against EBITDA is -6.53.

Stock Price History:

Over the past 52 weeks, MEDS has reached a high of $29.75, while it has fallen to a 52-week low of $2.46. The 50-Day Moving Average of the stock is 10.85, while the 200-Day Moving Average is calculated to be 8.22.

Shares Statistics:

The stock has traded on average 647.42K shares per day over the past 3-months and 119.29k shares per day over the last 10 days, according to various share statistics. A total of 1.21M shares are outstanding, with a floating share count of 0.85M. Insiders hold about 29.56% of the company’s shares, while institutions hold 5.66% stake in the company. Shares short for MEDS as of Mar 15, 2024 were 55.98k with a Short Ratio of 0.09, compared to 11.39k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.65% and a Short% of Float of 6.35%.

Earnings Estimates

Its stock is currently analyzed by 0 different market analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$0.9. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.

Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.

Revenue Estimates

1 analysts predict $2.28M in revenue for the current quarter. It ranges from a high estimate of $2.28M to a low estimate of $2.28M. As of the current estimate, Trxade Health Inc’s year-ago sales were $2.4M, an estimated decrease of -5.00% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $2.34M, a decrease of -7.50% less than the figure of -$5.00% in the same quarter last year. There is a high estimate of $2.34M for the next quarter, whereas the lowest estimate is $2.34M.

A total of 1 analysts have provided revenue estimates for MEDS’s current fiscal year. The highest revenue estimate was $8.93M, while the lowest revenue estimate was $8.93M, resulting in an average revenue estimate of $8.93M. In the same quarter a year ago, actual revenue was $11.45M, down -22.00% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $9.3M in the next fiscal year. The high estimate is $9.3M and the low estimate is $9.3M. The average revenue growth estimate for next year is up 4.10% from the average revenue estimate for this year.

Most Popular